Simon M M, Schaible U E, Wallich R, Kramer M D
Max-Planck-Institut für Immunbiologie, Freiburg, FRG.
Immunol Today. 1991 Jan;12(1):11-6. doi: 10.1016/0167-5699(91)90106-4.
Lyme disease is the most common vector-transmitted illness in the USA and Europe. The pathogen, Borrelia burgdorferi, causes a complex spectrum of disease that affects the skin, joints, nervous system and heart. Patients in the early stages of the disease can often be successfully treated with antibiotics but this becomes less reliable as the disease progresses. The specific immune responses that are detectable in patients with Lyme disease are not sufficient to protect against illness; a vaccine against the infectious agent is, therefore, desirable. In this article Markus M. Simon and colleagues present a mouse model of Borrelia burgdorferi infection. Their work suggests that the outer surface protein A (OspA) of Borrelia burgdorferi may be a suitable vaccine candidate.
莱姆病是美国和欧洲最常见的媒介传播疾病。病原体伯氏疏螺旋体可引发一系列复杂疾病，影响皮肤、关节、神经系统和心脏。处于疾病早期阶段的患者通常可用抗生素成功治疗，但随着疾病进展，这种治疗方法的可靠性会降低。在莱姆病患者中可检测到的特异性免疫反应不足以预防疾病；因此，需要一种针对该传染源的疫苗。在本文中，马库斯·M·西蒙及其同事展示了伯氏疏螺旋体感染的小鼠模型。他们的研究表明，伯氏疏螺旋体的外表面蛋白A（OspA）可能是一种合适的疫苗候选物。
